Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:4217 |
Name | malignant ovarian Brenner tumor |
Definition | A malignant ovarian surface epithelial-stromal neoplasm that has_material_basis_in the surface epithelium of the ovary. |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer organ system cancer reproductive organ cancer female reproductive organ cancer ovarian cancer ovary epithelial cancer malignant ovarian surface epithelial-stromal neoplasm malignant ovarian Brenner tumor |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
FGFR3 S249C | Erdafitinib | malignant ovarian Brenner tumor | predicted - sensitive | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT00565851 | Phase III | Gemcitabine Docetaxel + Paclitaxel Carboplatin Bevacizumab | Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer | Active, not recruiting | USA | 2 |
NCT01669798 | Phase II | Nintedanib | BIBF 1120 in Bevacizumab Resistant, Persistent, or Recurrent Epithelial Ovarian Cancer | Completed | USA | 0 |
NCT02068794 | Phase Ib/II | MV-NIS | MV-NIS Infected Mesenchymal Stem Cells in Treating Patients With Recurrent Ovarian Cancer | Active, not recruiting | USA | 0 |
NCT04931342 | Phase II | Cobimetinib Ado-trastuzumab emtansine Ipatasertib + Paclitaxel Atezolizumab + Bevacizumab | A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors | Active, not recruiting | USA | TUR | ITA | GBR | FRA | ESP | DEU | CZE | CHE | CAN | AUS | 2 |